^
Association details:
| Biomarker: | BTK expression + BCL2 expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinicopathologic and Prognostic Significance of Bruton’s Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma
Published date:
11/01/2021
Excerpt:
Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019)....BTK expression may be utilized to stratify risk in patients with DLBCL.
DOI:
10.21873/anticanres.15384
